|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IL10 polymorphism does not appear to be associated with MS or to influence disease progression.
|
10580805 |
1999 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-10 (IL-10) secretion affects the inducibility of experimental autoimmune encephalomyelitis and the outcome of multiple sclerosis (MS).
|
12039409 |
2002 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis.
|
15693804 |
2005 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-10 and miR-96 are associated with MS quiescence, however, the lack of a significant correlation between them implicates that the influence of miR-96 may be exhibited through some pathway other than IL-10.
|
31238191 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the size of the study group is small, these results indicate that polymorphic variations of two of the major anti-inflammatory cytokines, IL-10 and TGF-beta, may play a role in MS susceptibility.
|
16183136 |
2005 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of IL1A, IL1B, ILRN, IL6, IL10 and TNF-α polymorphisms with risk and clinical course of multiple sclerosis in a Polish population.
|
21621860 |
2011 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of the IL-10 receptor A536G (S138G) loss-of-function variant with multiple sclerosis in Tunisian patients.
|
28225209 |
2017 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Besides, the levels of anti-inflammatory cytokines include IL-4 and IL-10 was significantly higher in MS patients infected with HP when compared with MS patients seronegative for HP infection.
|
31610314 |
2019 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Blood samples from untreated patients diagnosed with clinically isolated syndrome (CIS) (<i>n</i> = 21), different clinical forms of MS (<i>n</i> = 62) [relapsing-remitting (RRMS), secondary progressive, and primary progressive], and healthy controls (HCs) (<i>n</i> = 17) were tested for plasma levels of interferon (IFN)-γ, IL-10, TGF-β, IL-17A, and IL-17F by immunoanalysis.
|
28713377 |
2017 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Both CMS and MS-SCON patients displayed reduced IL-8 and CXCL2 and increased TNF-α levels, while IL-10 and CXCL5 levels were identical among all groups.
|
31556809 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid IL-10 as an early stage discriminative marker between multiple sclerosis and neuro-Behçet disease.
|
29625335 |
2018 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Conclusion Peripheral blood CD19<sup>+</sup>CD24<sup>hi</sup>CD38<sup>hi</sup> Breg cell levels and serum IL-10 levels were reduced in MS patients compared with controls, but Breg cell levels were not correlated with MS EDSS score.
|
30025488 |
2018 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Correction to: Cycle ergometer training enhances plasma interleukin-10 in multiple sclerosis.
|
31115800 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cycle ergometer training enhances plasma interleukin-10 in multiple sclerosis.
|
31041609 |
2019 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis.
|
10360761 |
1999 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Elicitation of specific IL-10 production by peptide-specific T cells in MS and NMOSD patients indicates that a key element in antigen specific tolerance is activated with this approach.
|
30962374 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
|
27055778 |
2016 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators.
|
23517930 |
2013 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse.
|
9630160 |
1998 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we discuss the role of IL-10 in autoimmune diseases and examine its beneficial effects in cellular-based autoimmune diseases such as multiple sclerosis (MS) or its involvement in humoral-based autoimmune diseases such as systemic lupus erythematosus (SLE).
|
12220553 |
2003 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we evaluated whether targeted delivery of MSCs with triple PSGL1/SLeX/IL-10 engineering improves therapeutic outcomes in mouse experimental autoimmune encephalomyelitis (EAE), a murine model for human MS. We found PSGL-1/SLeX mRNA transfection significantly enhanced MSC homing to the inflamed spinal cord.
|
26584349 |
2016 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we identify an imbalance between the cytokines IFN-γ and IL-10 as a shared T<sub>reg</sub> signature present in patients with multiple sclerosis and under high-salt conditions.
|
30374130 |
2018 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution.
|
17481737 |
2007 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IFN-gamma and IL-10 mRNA levels were higher in MS patients than in other inflammatory neurological diseases.
|
9413269 |
1997 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IFN-β1a decreased IL-17 and increased IL-10 seric levels; IL-17 significantly correlated with MS activity; TGF-β1 activity is titer-dependent, increased levels were associated with IL-17 inhibition; NR patients to IFN-β1a will have initial high IL-17 and low IL-10 and TGF-β seric levels.
|
27306062 |
2017 |